Skip to main content

Advertisement

Table 5 WHO tumor response status (n, %) in the ITT and PP populations at Months 4 and 8 and Individual End of letrozole treatment

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

  Intent-to-treat population, N = 29 Per-protocol population, N = 25
  Month 4 Month 8 Individual End Month 4 Month 8 Individual End
Tumor response Clinical tumor assessment Clinical tumor assessment
   complete response 1 (3.5%) 1 (3.5%) 2 (6.9%) 1 (4.0%) 1 (4.0%) 2 (8.0%)
   partial response 15 (51.7%) 6 (20.7%) 19 (65.5%) 14 (56.0%) 3 (12.0%) 16 (64.0%)
   no change (stable disease) 5 (17.2%) 1 (3.5%) 4 (13.8%) 3 (12.0%) 0 (0.0%) 3 (12.0%)
   progressive disease 2 (6.9%) 0 (0.0%) 3 (10.3%) 2 (8.0%) 0 (0.0%) 3 (12.0%)
Missing observations 6 (20.7%) 21 (72.4%) 1 (3.5%) 5 (20.0%) 21 (84.0%) 1 (4.0%)
Tumor response Mammography Mammography
   complete response 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
   partial response 7 (24.1%) 2 (6.9%) 7 (24.1%) 5 (20.0%) 1 (4.0%) 5 (20.0%)
   no change (stable disease) 11 (37.9%) 1 (3.5%) 13 (44.8%) 10 (40.0%) 0 (0.0%) 11 (44.0%)
   progressive disease 1 (3.5%) 0 (0.0%) 1 (3.5%) 1 (4.0%) 0 (0.0%) 1 (4.0%)
Missing observations 10 (34.5%) 26 (89.7%) 8 (27.6%) 9 (36.0%) 24 (96.0%) 8 (32.0%)
Tumor response Breast ultrasound Breast ultrasound
   complete response 1 (3.5%) 1 (3.5%) 2 (6.9%) 1 (4.0%) 1 (4.0%) 2 (8.0%)
   partial response 13 (44.8%) 5 (17.2%) 16 (55.2%) 11 (44.0%) 2 (8.0%) 13 (52.0%)
   no change (stable disease) 6 (20.7%) 1 (3.5%) 8 (27.6%) 5 (20.0%) 1 (4.0%) 7 (28.0%)
   progressive disease 1 (3.5%) 0 (0.0%) 1 (3.5%) 1 (4.0%) 0 (0.0%) 1 (4.0%)
Missing observations 8 (27.6%) 22 (75.9%) 2 (6.9%) 7 (28.0%) 21 (84.0%) 2 (8.0%)